HIGHLIGHTS
- who: Marco Silvestri and colleagues from the Division Personalized Tumor Therapy, Fraunhofer-Institute for Toxicology and Experimental Medicine, Experimental Medicine and Therapy Research, University Regensburg, Franz-Josef-Strauss Allee, Milano, Italy have published the research work: Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients, in the Journal: (JOURNAL) of 15/01/2019
- what: Next, the authors focused on altered genomic regions shared among CTMs and tumor tissue from the same patients . The authors report that CTMs isolated from early-stage breast cancer patients contain genomically aberrant . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.